Results 181 to 190 of about 15,507,347 (338)
Molecular Oncology, EarlyView.Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou +11 more
wiley +1 more source
The diverse dependence of galectin-1 and -8 on multivalency for the modulation of FGFR1 endocytosis
Cell Communication and SignalingFibroblast growth factor receptor 1 (FGFR1) is a N-glycosylated cell surface receptor tyrosine kinase, which upon recognition of specific extracellular ligands, fibroblast growth factors (FGFs), initiates an intracellular signaling.
Dominika Żukowska +7 more
doaj +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
Molecular Oncology, EarlyView.mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia +17 more
wiley +1 more source
Molecular Oncology, EarlyView.MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin +14 more
wiley +1 more source
Molecular Oncology, EarlyView.Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane +16 more
wiley +1 more source
Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression
Molecular Oncology, EarlyView.Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park +6 more
wiley +1 more source
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
Molecular Oncology, EarlyView.We aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression‐based pathways with clinical outcomes. Loss of AR signaling, high proliferation, and a glycolytic phenotype were independently prognostic for poor outcomes, and an adverse transcriptional feature score incorporating these pathways ...
Marina N. Sharifi +26 more
wiley +1 more source
The Phyre2 web portal for protein modeling, prediction and analysis
Nature Protocols, 2015 L. Kelley +4 more
semanticscholar +1 more source
Protein-Protein and Protein-Ligand Docking [PDF]
, 2013 Aldo Yair Tenorio-Barajas +4 more
openaire +3 more sources
Molecular Oncology, EarlyView.TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam +9 more
wiley +1 more source